Fig. 4

Prevalence of patients meeting the criteria for metabolic syndrome by SGLT2i status (yes, no). Data are proportion of tirzepatide-treated patients with at least 3 diagnostic criteria for metabolic syndrome at the primary endpoint of 40/52 weeks by SGLT2i status (yes, no). MET: metformin; SGLT2i: sodium-glucose co-transporter 2 inhibitor; SU: sulfonylurea